LEADER 04387nam 2200625 a 450 001 9910791841603321 005 20230725021051.0 010 $a0-309-16157-6 010 $a1-282-78754-3 010 $a9786612787546 010 $a0-309-15655-6 035 $a(CKB)2560000000067684 035 $a(EBL)3378669 035 $a(SSID)ssj0000417460 035 $a(PQKBManifestationID)11290802 035 $a(PQKBTitleCode)TC0000417460 035 $a(PQKBWorkID)10361701 035 $a(PQKB)10274707 035 $a(MiAaPQ)EBC3378669 035 $a(Au-PeEL)EBL3378669 035 $a(CaPaEBR)ebr10420228 035 $a(CaONFJC)MIL278754 035 $a(OCoLC)923282191 035 $a(EXLCZ)992560000000067684 100 $a20101105d2010 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aExtending the spectrum of precompetitive collaboration in oncology research$b[electronic resource] $eworkshop summary /$fMargie Patlak, Sharyl J. Nass and Erin Balogh, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Institute of Medicine of the National Academies 210 $aWashington, D.C. $cNational Academies Press$d2010 215 $a1 online resource (113 p.) 300 $aDescription based upon print version of record. 311 $a0-309-15654-8 320 $aIncludes bibliographical references. 327 $a""Front Matter""; ""Reviewers""; ""Contents""; ""Boxes, Figures, and Tables""; ""Workshop Summary""; ""Acronyms""; ""Glossary""; ""Appendix A: Workshop Agenda""; ""Appendix B: Polling Results"" 330 $a"Despite spending more time and money in developing novel therapeutics, the success rate for new pharmacologic treatments has been poor. Although the research and development expenditures have grown 13 percent each year since 1970 (a 50-fold increase), the number of new drugs approved annually is no greater now than it was 50 years ago. Over the past decade, skyrocketing costs and the complexity of the scientific knowledge upon which to develop new agents have provided incentives for alternative approaches to drug development, if we are to continue to improve clinical care and reduce mortality. These challenges create opportunities for improved collaboration between industry, academia, government, and philanthropic organizations at each stage in new drug development, marketing, and implementation. Perhaps the most appropriate initial step in addressing the need for collaboration is to consider more precompetitive relationships that allow sharing of scientific information to foster drug development. 330 $aWhile these collaborative relationships in basic and preclinical research on drug targets and the early stages of clinical testing are acknowledged to be potentially important drivers for innovation and more rapid marketing of new agents, they also raise a number of concerns that must be addressed. For example, acknowledgment of academic productivity and independence and economic competitiveness must be considered and these challenges managed to foster a culture of collaboration. At the same time, regulatory issues, the need for standardization, and intellectual property concerns must be confronted if the current models for drug development are to be refined to encourage robust participation in precompetitive collaborations. Recognizing the growing importance of precompetitive collaborations in oncology drug development, as well as the challenges these innovative collaborations pose, the National Cancer Policy Forum of the Institute of Medicine held a workshop on February 9 and 10, 2010. This book is a summary of the workshop proceedings."--Publisher's description. 606 $aOncology$xResearch$vCongresses 615 0$aOncology$xResearch 676 $a616.994 700 $aPatlak$b Margie$01476477 701 $aPatlak$b Margie$01476477 701 $aNass$b Sharyl J$0857626 701 $aBalogh$b Erin$01089066 712 02$aNational Cancer Policy Forum (U.S.) 712 02$aInstitute of Medicine (U.S.).$bBoard on Health Care Services. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910791841603321 996 $aExtending the spectrum of precompetitive collaboration in oncology research$93691153 997 $aUNINA LEADER 01685nam 2200385Ia 450 001 996387464503316 005 20221108093329.0 035 $a(CKB)4940000000082108 035 $a(EEBO)2240938801 035 $a(OCoLC)ocm15666654e 035 $a(OCoLC)15666654 035 $a(EXLCZ)994940000000082108 100 $a19870511d1679 uy | 101 0 $aeng 135 $aurbn#|||a|bb| 200 14$aThe history of the reformation of the Church of England$hThe first part$b[electronic resource] $eof the progress made in it during the reign of K. Henry the VIII /$fby Gilbert Burnet 210 $aLondon $cPrinted by T.H. for Richard Chiswell ...$dMDCLXXIX [1679] 215 $a[18], 376, [2], 368, [4] p., [7] leaves of plates $cill., ports 300 $aIn two parts. Each part has special t.p. ans separate pagination. 300 $a"A collection of records and original papers, with other instruments referred to in the former history": p. [1]-304 of the third count. 300 $aIncludes engraved portraits, by Robert White, of Henry, Catherine of Aragon, Thomas Wolsey, Thomas Cranmer, Anne Boleyn, Thomas Cromwell, and Thomas More. 300 $aReproduction of original in the Cambridge University Library. 320 $aIncludes bibliographical references and indexes. 330 $aeebo-0021 606 $aReformation$zEngland 615 0$aReformation 700 $aBurnet$b Gilbert$f1643-1715.$0193326 701 $aWhite$b Robert$f1645-1703.$0845954 801 0$bEAK 801 1$bEAK 801 2$bWaOLN 906 $aBOOK 912 $a996387464503316 996 $aThe history of the reformation of the Church of England$92359688 997 $aUNISA